Biology of interleukin-10 and its regulatory roles in sepsis syndromes

Critical Care Medicine

Volumn 33, Issue 12 SUPPL., 2005, Pages

  Scumpia, Philip O ^a   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 1; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEUTRALIZING ANTIBODY; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; CELL POPULATION; CYTOKINE PRODUCTION; DNA POLYMORPHISM; HELPER CELL; HOSPITALIZATION; HUMAN; INFLAMMATION; INTENSIVE CARE; KNOCKOUT MOUSE; MACROPHAGE; MAST CELL; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEPSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 28944445060     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000186268.53799.67     Document Type: Article

References (39)

1. Fiorentino DF, Bond MW, Mosmann TR: Two types of mouse T helper cell: IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-2095
2. Josephson K, DiGiacomo R, Indelicato SR, et al: Design and analysis of an engineered human interleukin-10 monomer. J Biol Chem 2000; 275:25054
3. Moore KW, de Waal Malefyt R, Coffman RL, et al: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765
4. O'Garra A, Vieira PL, Vieira P, et al: IL-10-producing and naturally occurring CD4+ Tregs: Limiting collateral damage. J Clin Invest 2004; 114:1372-1378
5. Wakkach A, Fournier N, Brun V, et al: Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605-617
6. van der Poll T, Jansen J, Levi M, et al: Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180:1985-1988
7. Kuhn R, Lohler J, Rennick D, et al: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-274
8. Berg DJ, Kuhn R, Rajewsky K, et al: Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96:2339-2347
9. Marchant A, Deviere J, Byl B, et al: Interleukin-10 production during septicaemia. Lancet 1994; 343:707-708
10. Lehmann AK, Halstensen A, Sornes S, et al: High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63:2109-2112
11. Marchant A, Alegre ML, Hakim A, et al: Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15:266-273
12. Friedman G, Jankowski S, Marchant A, et al: Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997; 12:183-187
13. Neidhardt R, Keel M, Steckholzer U, et al: Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997; 42:863-870; discussion, 870-861
14. Ertel W, Keel M, Neidhardt R, et al: Inhibition of the defense system stimulating interleukin-12 interferon-gamma pathway during critical Illness. Blood 1997; 89:1612-1620
15. Oberholzer A, Oberholzer C, Moldawer LL: Interleukin-10: A complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002; 30(1 Suppl):S58-S63
16. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128
17. van Dissel JT, van Langevelde P, Westendorp RG, et al: Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-953
18. Turner DM, Williams DM, Sankaran D, et al: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8
19. Eskdale J, Keijsers V, Huizinga T, et al: Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999; 1:151-155
20. Westendorp RG, Langermans JA, Huizinga TW, et al: Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349:1912-1913
21. van der Pol WL, Huizinga TW, Vidarsson G, et al: Relevance of Fc gamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 2001; 184:1548-1555
22. Balding J, Healy CM, Livingstone WJ, et al: Genomic polymorphic profiles in an Irish population with meningococcaemia: Is it possible to predict severity and outcome of disease? Genes Immun 2003; 4:533-540
23. Lowe PR, Galley HF, Abdel-Fattah A, et al: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31:34-38
24. Reid CL, Perrey C, Pravica V, et al: Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med 2002; 30:2216-2221
25. Gallagher PM, Lowe G, Fitzgerald T, et al: Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58:154-156
26. Schaaf BM, Boehmke F, Esnaashari H, et al: Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168:476-480
27. Stuber F: Another definite candidate gene for genetic predisposition of sepsis: Interleukin-10. Crit Care Med 2003; 31:314-315
28. van Roon J, Wijngaarden S, Lafeber FP, et al: Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc gamma receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol 2003; 30:648-651
29. Kumar A, Zanotti S, Bunnell G, et al: Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response. Crit Care Med 2005; 33:331-340
30. Lauw FN, Pajkrt D, Hack CE, et al: Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165:2783-2789
31. Nelson DR, Tu Z, Soldevila-Pico C, et al: Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38:859-868
32. Remick DG, Garg SJ, Newcomb DE, et al: Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 1998; 26:895-904
33. Steinhauser ML, Hogaboam CM, Kunkel SL, et al: IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999; 162:392-399
34. Oberholzer C, Oberholzer A, Bahjat FR, et al: Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Nat Acad Sci U S A 2001; 98:11503-11508
35. Oberholzer A, Oberholzer C, Bahjat KS, et al: Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. J Immunol 2002; 168:3412-3418
36. Oberholzer A, Oberholzer C, Efron PA, et al: Functional modification of dendritic cells with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis. Shock 2005; 23:507-515
37. Zhu M, Wei MF, Liu F, et al: Interleukin-10 modified dendritic cells induce allo-hyporesponsiveness and prolong small intestine allograft survival. World J Gastroenterol 2003; 9:2509-2512
38. Mahnke K, Schmitt E, Bonifaz L, et al: Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002; 80:477-483
39. Jones BC, Logsdon NJ, Josephson K, et al: Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Nat Acad Sci U S A 2002; 99:9404-9409